MedTrace Logo

Effectiveness of the Diabetes Body Project Among Females With Type 1 Diabetes

NCT04837989 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2023-08-04

No results posted yet for this study

Summary

Young females with type 1 diabetes (T1D) is at high risk of eating disorders (ED), with prevalence rates of ED more than double those of non-diabetes peers. T1D and ED are both associated with serious somatic complications, and when occurring together the prognosis is even worse. Despite the frequency and severity of this comorbidity, there is a lack of intervention studies and no consensus on how to best prevent and treat this comorbidity. To remedy this, we have developed a virtual diabetes-adapted version of the ED prevention program Body Project, i.e. the Diabetes Body Project. This study examines the effectiveness of the Diabetes Body Project to reduce ED risk factors and symptoms among young females with T1D.

Conditions

  • Feeding and Eating Disorders
  • Diabetes Mellitus, Type 1
  • Body Image

Interventions

BEHAVIORAL

Diabetes Body Project

Six virtually delivered Diabetes Body Project groups over six weeks (one hour a week); 5-6 participants and 2 group facilitators

BEHAVIORAL

Psychoeducation

Individuals assigned to the psychoeducational control condition will receive an educational brochure, and complete similar assessments and assessment time points as the experimental condition. Individuals in the control group will be offered Diabetes Body Project group participation after six months.

Sponsors & Collaborators

  • The Dam Foundation

    collaborator OTHER

  • Norwegian Diabetes Association

    collaborator OTHER

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Line Wisting, PhD · Oslo University Hospital, Division of Mental Health and Addiction

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-07-31
Completion
2022-07-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04837989 on ClinicalTrials.gov